MZE001

About Maze Therapeutics

Maze Therapeutics is a biotechnology company that maps the connections between genetic variants and disease to develop novel therapeutics. The company's core Compass platform integrates human genetics, functional genomics, and data science to identify protective genetic modifiers, which serve as blueprints for drug development. Maze has advanced its lead candidate, MZE001 for APOL1-mediated kidney disease, into Phase 2 clinical trials and secured significant funding, including a $190 million Series C and a strategic partnership with Sanofi. The company aims to build a pipeline of precision medicines for patients with high unmet need.

Therapeutic Areas